| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Spago Nanomedical AB Q3 Loss Decreases | 2 | RTTNews | ||
| 05.11. | Spago Nanomedical Interim Report January-September 2026 | 343 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 0 (KSEK 14)The loss for the quarter amounted... ► Artikel lesen | |
| 23.10. | Spago Nanomedical AB (publ) receives observation status | 422 | GlobeNewswire | Yesterday, October 22, 2026, Spago Nanomedical AB (publ) (the "Company") issued a press release stating that the Company's board of directors had resolved to apply for the removal of the Company's... ► Artikel lesen | |
| 22.10. | The Board of Directors of Spago Nanomedical Has Resolved, Subject to the Approval of the General Meeting, to Apply for Delisting From the NASDAQ First North Growth Market | 454 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 22, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Board of Directors of Spago Nanomedical AB (publ), company registration number 556574-5048 ("Spago Nanomedical"... ► Artikel lesen | |
| 22.10. | Notice of Extraordinary General Meeting in Spago Nanomedical AB | 399 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 22, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The shareholders of Spago Nanomedical AB (publ), corporate registration number 556574-5048 ("Spago Nanomedical"... ► Artikel lesen | |
| 22.10. | Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB | 271 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 22, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Extraordinary General Meeting of Spago Nanomedical AB (publ) was held today, October 22, 2026, at which... ► Artikel lesen | |
| 22.10. | Spago Nanomedical AB: Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB | 158 | GlobeNewswire (Europe) | The Extraordinary General Meeting of Spago Nanomedical AB (publ) was held today, October 22, 2026, at which the following resolutions were passed.
The Extraordinary General Meeting resolved to implement... ► Artikel lesen | |
| 29.09. | Spago Nanomedical to Participate in Several International Industry Conferences During Autumn 2026 | 429 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 29, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) today announces that the company will participate in five international conferences during autumn... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 21.09. | Notice Of Extraordinary General Meeting in Spago Nanomedical AB | 356 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 21, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The shareholders of Spago Nanomedical AB (publ), corporate registration number 556574-5048, are hereby... ► Artikel lesen | |
| 20.08. | Spago Nanomedical AB Q2 Sales Decline | 2 | RTTNews | ||
| 20.08. | Spago Nanomedical Interim Report January-June 2026 | 557 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 20, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 0 (KSEK 81)The loss for the quarter amounted... ► Artikel lesen | |
| 18.06. | Spago Nanomedical AB: Spago Nanomedical announces outcome of rights issue | 320 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 10.06. | Bulletin from the 2026 Annual General Meeting of Spago Nanomedical AB | 399 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2026, at which the... ► Artikel lesen | |
| 03.06. | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 524 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 03.06. | Spago Nanomedical AB: The subscription period in Spago Nanomedical's rights issue begins today | 243 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 02.06. | Listing of subscription rights and paid subscription shares of Spago Nanomedical AB | 346 | GlobeNewswire | With effect from June 03, 2026, the subscription rights in Spago Nanomedical AB will be traded on First North Growth Market. Trading will continue up until and including June 12, 2026.
... ► Artikel lesen | |
| 02.06. | Spago Nanomedical AB: Spago Nanomedical publishes information document in connection with forthcoming rights issue | 221 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 29.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | 601 | Xetra Newsboard | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen | |
| 22.05. | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 16 Million | 500 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 19.05. | Spago Nanomedical Publishes the Annual Report for 2025 | 455 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2025 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |